Sonoma Pharmaceuticals Inc (NASDAQ:SNOA) saw strong trading volume on Thursday . 5,684,113 shares were traded during trading, an increase of 4,643% from the previous session’s volume of 119,831 shares.The stock last traded at $1.20 and had previously closed at $1.10.

A number of analysts recently issued reports on the stock. Zacks Investment Research downgraded shares of Sonoma Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, August 29th. Maxim Group restated a “hold” rating on shares of Sonoma Pharmaceuticals in a report on Friday, November 9th. Benchmark restated a “speculative buy” rating and set a $3.00 price objective on shares of Sonoma Pharmaceuticals in a report on Friday, July 20th. Finally, ValuEngine upgraded shares of Sonoma Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Wednesday, September 12th.

The company has a current ratio of 3.80, a quick ratio of 2.84 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $7.32 million, a price-to-earnings ratio of -0.38 and a beta of 1.31.

Sonoma Pharmaceuticals (NASDAQ:SNOA) last issued its earnings results on Thursday, November 8th. The company reported ($0.44) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.02. The firm had revenue of $4.94 million during the quarter. Sonoma Pharmaceuticals had a negative net margin of 79.91% and a negative return on equity of 107.44%. As a group, equities analysts expect that Sonoma Pharmaceuticals Inc will post -2 earnings per share for the current fiscal year.

A hedge fund recently raised its stake in Sonoma Pharmaceuticals stock. Renaissance Technologies LLC grew its holdings in shares of Sonoma Pharmaceuticals Inc (NASDAQ:SNOA) by 54.6% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 91,095 shares of the company’s stock after purchasing an additional 32,180 shares during the quarter. Renaissance Technologies LLC owned about 1.41% of Sonoma Pharmaceuticals worth $226,000 at the end of the most recent reporting period. 11.34% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY WARNING: “Sonoma Pharmaceuticals (SNOA) Sees Strong Trading Volume” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this news story on another website, it was copied illegally and republished in violation of U.S. and international copyright law. The original version of this news story can be accessed at

About Sonoma Pharmaceuticals (NASDAQ:SNOA)

Sonoma Pharmaceuticals, Inc, a specialty pharmaceutical company, develops and markets solutions for the treatment of chronic skin conditions and advanced tissue care in the United States and internationally. The company offers Levicyn, a hypochlorous acid (HOCl) based prescription product to manage and relieve burning, itching, and pain experienced with various types of dermatoses; Celacyn gel, a product indicated to promote healing through the management of new and old scars resulting from surgical procedures and trauma wounds or burns; SebuDerm, a product indicated to manage and relieve the burning, itching, pain, and distraction associated with seborrhea and seborrheic dermatitis; and Ceramax, a Lipogrid based skin barrier cream indicated to relieve and manage the burning and itching associated with various skin conditions.

Recommended Story: What is a capital gain?

Receive News & Ratings for Sonoma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sonoma Pharmaceuticals and related companies with's FREE daily email newsletter.